Centene is set to participate in CMS’ GLP-1 bridge program for Medicare Part D. CEO Sarah London confirmed this move during the company’s April 28 earnings call. The announcement comes as the broader BALANCE model faces an indefinite pause for Medicare, creating both uncertainty and opportunity for major insurers.
What Is the BALANCE Model?
Understanding CMS’ GLP-1 Initiative
The BALANCE model stands for “Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth.” CMS designed this initiative to use negotiated GLP-1 drug prices across both Medicaid and Medicare Part D. The primary goal is expanding access to weight-loss medications for eligible beneficiaries. Beyond drug coverage, the model also incorporates lifestyle-focused programs to support long-term health outcomes.
Why GLP-1 Drugs Matter for Medicare
GLP-1 receptor agonists have transformed obesity and diabetes treatment. However, their high cost puts them out of reach for many seniors on fixed incomes. Medicare has historically had limited coverage for weight-loss drugs. As a result, the BALANCE model represents a significant shift in federal health policy.
How the Bridge Program Works
Bridging the Gap Before Full Rollout
The bridge demo serves as an on-ramp to the full BALANCE model. It gives eligible Medicare Part D beneficiaries some access to GLP-1 medications starting July 1, 2026. CMS extended the bridge’s end date to December 31, 2027, giving more time for data collection and evaluation.
Who Is Eligible
The bridge program targets Part D enrollees who meet specific criteria for weight management under the program’s guidelines. Centene’s participation means its Medicare members can now benefit from this early access pathway.
Centene’s Position on GLP-1 Access
CEO Sarah London’s Statement
London expressed clear support for the initiative. “We are pleased that our Medicare members will have the opportunity to participate in the CMS bridge program, and we support the goal of expanded GLP-1 access for more seniors,” she said.
A Broader Commitment to BALANCE
Furthermore, London indicated that Centene is actively engaged in dialogue around the full BALANCE model. She stated that the company remains committed to partnering with the administration. The insurer intends to use data and lessons from the bridge program to help position BALANCE for future success.
UnitedHealthcare’s Cautious Interest
Another Major Insurer Eyes the Bridge
Centene is not alone in considering participation. UnitedHealthcare also expressed interest in the GLP-1 bridge demo during its April 21 earnings call. However, the carrier raised concerns about the broader model’s structure.
Outstanding Questions Remain
Bobby Hunter, UnitedHealthcare’s CEO of government programs, noted the complexity. “We’d like to find a path to ‘yes’ there on coverage over time, but there are some notable challenges and outstanding questions with the currently planned structure,” he said. This reflects a cautious, wait-and-see posture from one of the nation’s largest Medicare Advantage insurers.
CMS Pauses the BALANCE Medicare Pilot
Why the Full Model Stalled
Shortly after UnitedHealthcare’s earnings call, CMS confirmed that it is holding off on launching the BALANCE pilot for Medicare Part D. The pilot was originally set to begin in 2027. CMS required Part D plan sponsors representing at least 80% of total Part D enrollment to apply for the model to move forward. The April 20 application deadline passed without that threshold being met.
Medicaid Applications Still Open
State Medicaid programs, however, can still apply to participate through July 31. This keeps part of the initiative alive while CMS reassesses its Medicare approach.
Unresolved Challenges Facing BALANCE
KFF Analysis Flags Key Concerns
A March analysis by KFF highlighted several unresolved issues with the BALANCE model. Specifically, analysts pointed to open questions around implementation logistics, medication adherence monitoring, regulatory alignment, and operational feasibility. These concerns likely contributed to the low uptake among Part D sponsors ahead of the application deadline.
Industry-Wide Caution
While GLP-1 access is a clear priority for many payers and patient advocates, the structural complexity of the BALANCE model has made full commitment difficult. Both insurers and policymakers appear to see the bridge program as a useful, lower-risk stepping stone.
What This Means for Medicare Members
Near-Term Access Starting Mid-2026
For eligible Centene Medicare members, the practical impact is meaningful. Access to GLP-1 medications through the bridge program begins July 1, 2026. This provides near-term relief while the industry waits for a viable path to the full BALANCE rollout.
A Critical Moment for Obesity Coverage Policy
The bridge program and the BALANCE model together signal a turning point in how federal programs approach obesity treatment. Moreover, Centene’s active participation puts it ahead of many peers in aligning with CMS priorities. How the bridge performs over the next 18 months will likely shape the future structure of GLP-1 coverage under Medicare.
